Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviour.

Journal of Neurochemistry
Fiona E HolmesDavid Wynick

Abstract

There is increasing evidence that a number of cytokines and their receptors are involved in the processes that lead to the development and maintenance of neuropathic pain states. Here we demonstrate that levels of CX3CR1 (the receptor for the chemokine fractalkine) mRNA in lumbar dorsal root ganglia (DRG) increase 5.8-fold 7 days after sciatic nerve axotomy, and 1.7- and 2.9-fold, 3 and 7 days respectively, after the spared nerve injury (SNI) model of neuropathic pain. In contrast, no significant change in the levels of fractalkine mRNA is apparent in the DRG after axotomy or SNI. The increase in CX3CR1 mRNA is paralleled by a 3.9- and 2.1-fold increase in the number of CX3CR1-positive macrophages in the DRG 7 days after axotomy and SNI, respectively. Expression of CX3CR1 in macrophages is also markedly increased in the sciatic nerve proximal to site of injury, by 25.7-fold after axotomy and 16.2-fold after SNI, 7 days after injury. Intra-neural injection into the sciatic nerve of 400 ng or 100 ng of fractalkine in adult 129OlaHsd mice significantly delayed the development of allodynia for 3 days following SNI. Further, CX3CR1 knockout (KO) mice display an increase in allodynia for three weeks after SNI compared to strain-match...Continue Reading

References

Jan 1, 1980·Annual Review of Pharmacology and Toxicology·W J Dixon
Jul 1, 1994·Journal of Neuroscience Methods·S R ChaplanT L Yaksh
Feb 13, 1997·Nature·J F BazanT J Schall
Jun 19, 1998·Brain Research. Molecular Brain Research·D ItoS Kohsaka
Sep 2, 1998·Proceedings of the National Academy of Sciences of the United States of America·J K HarrisonL Feng
Jan 27, 1999·Biochemical and Biophysical Research Communications·C CombadiereP M Murphy
Mar 16, 2000·Proceedings of the National Academy of Sciences of the United States of America·A SaccaniA Sica
Jun 28, 2000·Proceedings of the National Academy of Sciences of the United States of America·O MeucciR J Miller
Sep 26, 2001·The Journal of Biological Chemistry·C L TsouI F Charo
Jun 5, 2002·Neuroscience·M-Z YaoX-Y Liu
Jul 20, 2002·Proceedings of the National Academy of Sciences of the United States of America·Imre SzaboThomas J Rogers
Dec 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Mariana L ValeRonaldo A Ribeiro
Feb 26, 2003·Circulation·Christophe CombadièreZiad Mallat
May 2, 2003·Proceedings of the National Academy of Sciences of the United States of America·Fiona E HolmesDavid Wynick
Jun 10, 2003·The Journal of Comparative Neurology·Julie M SrogaPhillip G Popovich
Jun 20, 2003·Journal of Neuroscience Research·G TarozzoM Beltramo
Jul 10, 2003·Brain Research·Tetsuya MizunoAkio Suzumura
Nov 19, 2003·The Journal of Pain : Official Journal of the American Pain Society·Shannon D ShieldsAllan I Basbaum
Mar 30, 2004·The Journal of Biological Chemistry·Niall C H KerrDavid Wynick
Oct 16, 2004·Critical Reviews in Immunology·Laura StievanoAlberto Amadori
Nov 5, 2004·The European Journal of Neuroscience·E D MilliganL R Watkins
Nov 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Toshihiro NankiNobuyuki Miyasaka
Mar 2, 2005·European Journal of Pain : EJP·H L Rittner, C Stein
Mar 15, 2005·Proceedings of the National Academy of Sciences of the United States of America·Ning ZhangJoost J Oppenheim
Jul 5, 2005·The Journal of Pain : Official Journal of the American Pain Society·Jill A LindiaCatherine Abbadie
Jul 16, 2005·Journal of Neuroimmunology·Cristina LimatolaFabrizio Eusebi
Jul 19, 2005·The Journal of Pharmacology and Experimental Therapeutics·Waldiceu A VerriFernando Q Cunha
Jul 22, 2005·Immunology and Cell Biology·Philippa Hillyer, David Male
Jul 28, 2005·Journal of Neuroscience Research·Xiaomei QinXian Wang
Aug 16, 2005·Trends in Immunology·Catherine Abbadie
Oct 15, 2005·Nature Reviews. Drug Discovery·Fletcher A WhiteRichard J Miller
May 30, 2006·Nature Neuroscience·Astrid E CardonaRichard M Ransohoff
Jul 4, 2006·Neuropharmacology·Cristina BertolliniFabrizio Eusebi

❮ Previous
Next ❯

Citations

Jun 19, 2013·Proceedings of the National Academy of Sciences of the United States of America·Guilherme R SouzaSérgio H Ferreira
May 21, 2014·Experimental Neurology·Kasper C D Roet, Joost Verhaagen
Feb 2, 2010·Pharmacology & Therapeutics·Yong-Jing Gao, Ru-Rong Ji
Aug 21, 2015·Molecular and Cellular Neurosciences·Niall KerrDavid Wynick
Sep 21, 2015·Neurochemical Research·Yonghong DingZongwang Zhang
Oct 25, 2011·Current Opinion in Pharmacology·Norikazu KiguchiShiroh Kishioka
Apr 9, 2017·Cellular and Molecular Life Sciences : CMLS·Zhi-Jun ZhangYong-Jing Gao
Jan 21, 2009·Laboratory Investigation; a Journal of Technical Methods and Pathology·Güralp O CeyhanHelmut Friess
Jan 9, 2010·Expert Opinion on Therapeutic Targets·Jan G D'HaeseGüralp O Ceyhan
Jun 15, 2017·Proceedings of the National Academy of Sciences of the United States of America·Nassir MokarramRavi V Bellamkonda
May 26, 2020·Pharmacology & Therapeutics·Bao-Chun JiangYong-Jing Gao

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.